Table 4.
Univariate and multivariate analyses of certain factors for clinical relapse-free survival in 121 patients treated with IMRT with or without regional hyperthermia.
| Variation | Patients (n) | Univariate | Multivariate | |||
|---|---|---|---|---|---|---|
| 5-y (%) | p * | Hazard Ratio ** (95% CI) | p | Hazard Ratio (95% CI) | ||
| T stage | ||||||
| T1–T2 | 99 | 94.2 | 0.5391 | 0.601 (0.116–3.107) | 0.564 | 0.600 (0.106–3.403) |
| T3a | 22 | 93.3 | ||||
| Gleason score | ||||||
| ≤8 | 78 | 95.7 | 0.5723 | 0.651 (0.145–2.920) | 0.317 | 0.455 (0.097–2.125) |
| ≥9 | 43 | 90.3 | ||||
| Pretreatment PSA (ng/mL) | ||||||
| ≤20 | 72 | 92.8 | 0.5504 | 0.610 (0.118–3.144) | 0.597 | 0.612 (0.100–3.766) |
| >20 | 49 | 95.5 | ||||
| Total ADT (months) | ||||||
| ≤10 | 70 | 91.5 | 0.1592 | 0.246 (0.030–2.043) | 0.121 | 0.170 (0.018–1.599) |
| >10 | 51 | 97.4 | ||||
| Hyperthermia | ||||||
| Yes | 70 | 98.0 | 0.0229 | 0.126 (0.015–1.049) | 0.035 | 0.099 (0.000–0.852) |
| None | 51 | 88.6 | ||||
* Log-rank test. ** Hazard ratio and 95% confidence interval were calculated using the Wald test. CI, confidence interval; PSA, prostate-specific antigen; ADT, androgen deprivation therapy.